Markets
Karyopharm Endometrial Cancer Trial Misses Primary Endpoint: What Traders Need to Know
Karyopharm Therapeutics suffered a significant clinical setback after its endometrial cancer trial failed to meet its primary endpoint, triggering a sharp reassessment of the company's pipeline value and near-term revenue potential. Here is what the data failure means for KPTI stock and how traders should position around the wreckage.